Navigation
banner

Cancer Therapeutics & Partnering Summit 2017

2017-10-242017-08-282017-07-28
Register 3 for the price of 2 with the coupon code rcdvb!


ssclaas=mixsessionprlval=1Array ( [6] => 1 )
Day 1 - Thursday, September 28th, 2017
7:30
Continental Breakfast & Registration
ssclaas=mixsessionprlval=1Array ( [6] => 1 )
ssclaas=mixsessionprlval=1Array ( [6] => 1 )
ssclaas=mixsessionprlval=1Array ( [6] => 1 )
10:00
Morning Networking Break
ssclaas=parallelprlval=1Array ( [343] => 1 [6] => 1 )
Oncology Partnering & Deal-Making 2017
What’s New in Oncology – Targets, Models, Assays
Moderator: Aaron Miscenich, New Orleans BioInnovation Center
10:45
Development of an NGS-Based CDx Assay for Multiple Drug Targets Across Solid Tumor Malignancies in Plasma and FFPE
 
Jill  Stefanelli
Jill Stefanelli
Senior Director of Diagnostic Development
ArcherDX, INC.
About Speaker: ... Read Full Bio 
 
 
Jill  Stefanelli
Jill Stefanelli
Senior Director of Diagnostic Development
ArcherDX, INC.
 
About Speaker:
 
Abstract: Recurrent genetic mutations as well a...Read More 

Recurrent genetic mutations as well as rearrangements involving numerous tyrosine kinases including genes like EGFR, ALK, ROS1 and NTRK1/2/3 have the potential to be oncogenic drivers.  Clinical utility has been demonstrated in non-small cell lung cancer (NSCLC) for EGFR exon 19 deletions and exon 21 L858R and BRAF V600E substitution mutations as well as gene fusions with ALK or ROS1.  In addition to these, additional genes are currently targeted in various phases of clinical development and are often present in small proportions of a variety of tumor types, including NSCLC, colorectal cancer, breast cancer, melanoma cancer, salivary gland cancer, papillary thyroid cancer, melanoma and sarcoma making them challenging to detect for potential patient enrollment. We are developing a universal CDx assay based on the ArcherDX AMP technology to be used as a “one test, multiple drug” approach to solve some of the current challenges including sufficient sample material, development and regulatory costs.  This assay can interrogate DNA and RNA simultaneously, and has great potential to address many challenges with single gene based approaches.  In this approach, multiple pharmaceutical companies can align to develop a product which life cycle manages current therapeutics with demonstrated clinical utility as well as future drugs and utility. As the industry moves to rare target specific compounds, close interaction between pharmaceutical and diagnostic developers will be critical to identify, select, and enroll enough patients for a successful trial outcome and drug approval.

 Read Less
Complementary & Companion Diagnostics in Oncology 2017
Technologies and Biomarkers
Moderator: Eric Lindquist, Natera
10:45
Companion Diagnostics 20 Years Later. Where Do We Go From Here?
 
Eric  Lindquist
Eric Lindquist
Vice President of Pharma Business Development
Natera
About Speaker: Eric has over 20 years of experience in the precision medicine space. Eric was trained in cytogenetics but started his commercial career at Abbott Molecular selling the first DNA based FDA approved and cleared companion diagnostic assays to directly ... Read Full Bio 
 
 
Eric  Lindquist
Eric Lindquist
Vice President of Pharma Business Development
Natera
 
About Speaker:

Eric has over 20 years of experience in the precision medicine space. Eric was trained in cytogenetics but started his commercial career at Abbott Molecular selling the first DNA based FDA approved and cleared companion diagnostic assays to directly to laboratories and clinicians.  Eric has also worked for Johnson and Johnson in their Veridex group enabling pharmaceutical companies to incorporate rare cells into their clinical trials. Eric then worked at Roche where he executed a number of public and non-public companion diagnostic agreements.  Eric also led the Translational Diagnostics team at Asuragen.  While at Asuragen, Eric’s team executed an umbrella agreement with lllumina enabling Asuragen to be the first 3rd party company to have CDx developed FTO on the MiSeq platform.   Eric has also consulted for a significant number of diagnostic and pharmaceutical regarding their companion diagnostic partnership, development, and commercialization strategies and tactics.

 
Abstract: We’ve been on the companion dia...Read More 

We’ve been on the companion diagnostic path for over 20 years now.  However, well defined diagnostic and biopharmaceutical company co-development truly started less ten years ago.  What were the mistakes of the past 20 years?  What were the successes?  What are the future challenges?  What do we need to focus on to make companion diagnostic co-development successful going forward?

 Read Less
ssclaas=parallelprlval=1Array ( [343] => 1 [6] => 1 )
11:10
Pharmaceutical-Diagnostic Partnerships: A Case Study – The Challenges and Opportunities
 
Chris  Meda
Chris Meda
Chief Business Officer
IncellDx
About Speaker: Ms. Meda, currently CBO at IncellDx, has 30 years of leadership in the global diagnostic and pharmaceutical industries. Her management responsibilities have ranged from VP to President to CEO where she created worldwide strategic business directi... Read Full Bio 
 
 
Chris  Meda
Chris Meda
Chief Business Officer
IncellDx
 
About Speaker:

Ms. Meda, currently CBO at IncellDx, has 30 years of leadership in the global diagnostic and pharmaceutical industries. Her management responsibilities have ranged from VP to President to CEO where she created worldwide strategic business direction and plans, operations and commercialization of more than 30 products for various disease areas at Hoffman-LaRoche, Schering AG pharmaceuticals, Bio-Rad Laboratories, Diagnostics Products Corporation (now Siemens), Meridian Diagnostics. She is CBO at IncellDx, a single cell diagnostic company focused on multiplex RNA in situ Hybridization, multiplex Protein Detection, DNA/Cell Cycle, simultaneously detection in Every Cell. She is National Chair of Women in BIO-Sponsorship, an organization of professionals committed to promoting careers, leadership, and entrepreneurship of women in the life sciences; and, a Board Director for Claremont BioSolutions, a company providing laboratories with diagnostics and devices for molecular diagnostics and bioscience research. Prior to IncellDx, Ms. Meda was President of Response Genetics (RGI), a precision medicine company that has developed PCR-based genetics tests for lung, colon, gastric and melanoma cancers which help medical oncologists with therapeutic treatment decisions for patients with these cancer types. Prior to RGI, she was CEO, President at Arcxis Biotechnologies a venture backed start-up with a focus on molecular diagnostic extraction devices and reagents. Arcxis was sold to Fluidigm in September, 2010. At Hoffman-LaRoche, Chris was VP of the Roche Molecular Diagnostics Division for the Global Women’s Health and subsequently became Vice President of Business Development. Her leadership role and portfolio responsibilities included global strategic planning for the portfolio, oversight of research and development and the commercialization of PCR-based diagnostics for Human Papillomavirus, Chlamydia, Herpes Simplex Virus and Group B Streptococcus. Her business development role was focused on companion diagnostics where she completed agreements between Roche Molecular Diagnostics and four pharmaceutical companies.

11:10
G Protein Coupled Receptors (GPCRs): Untapped Opportunities for Cancer Diagnosis and Therapy
 
Paul  Insel
Paul Insel
Distinguished Professor, Depts. of Medicine and Pharmacology
University of California, San Diego
About Speaker: Dr. Insel received his M.D. from the University of Michigan, clinical training at Boston City Hospital (Harvard Medical Service), and research training at NIH and UC San Francisco (UCSF). He joined the UCSF faculty and llater relocated to UC San... Read Full Bio 
 
 
Paul  Insel
Paul Insel
Distinguished Professor, Depts. of Medicine and Pharmacology
University of California, San Diego
 
About Speaker:

Dr. Insel received his M.D. from the University of Michigan, clinical training at Boston City Hospital (Harvard Medical Service), and research training at NIH and UC San Francisco (UCSF). He joined the UCSF faculty and llater relocated to UC San Diego (UCSD), where he is Distinguished Professor of Pharmacology and Medicine and Co-Director of the Medical Scientist (MD/PhD) Training Program. Dr. Insel’s research efforts focus on G-protein-coupled receptors (GPCRs) and include studies of GPCR expression, G-proteins, G-protein-regulated effectors, and signaling compartmentation in lipid rafts/caveolae. Dr. Insel has published >280 original articles and 160 invited articles/reviews. He has served as Editor-in-Chief of numerous scientific journals, including the Journal of Clinical Investigation, Molecular Pharmacology, and American Journal of Physiology-Cell Physiology. Currently, he is Editor, Annual Review of Pharmacology and Toxicology; Senior Editor, British Journal of Pharmacology and co-Head of Faculty, Faculty of 1000Prime in Pharmacology and Drug Discovery. Dr. Insel holds a Doc. Hon Causa from the University of Paris, is a Fellow, American Association for the Advancement of Science and has received awards from the American Physiological Society, Dutch Pharmacology Society and American Society for Pharmacology and Experimental Therapeutics.

 
Abstract: G protein-coupled receptors (GPCRs), ...Read More 

G protein-coupled receptors (GPCRs), the most highly expressed membrane signaling receptors in humans, are also the most widely targeted class of FDA-approved therapeutics. Surprisingly, though, GPCRs are not commonly targets for cancers other than endocrine tumors. Recent data from my laboratory and others has suggested that GPCRs may have been “missed” as targets in cancer, perhaps in part because they have not been identified as driver mutations. Recent data reveals that numerous GPCRs have substantially increased expression in numerous types of tumors and thus, that such GPCRs may have unappreciated utility as therapeutic targets in a variety of cancers. My laboratory has used unbiased approaches (Taqman GPCR arrays and RNA-seq), mining of publicly available datasets (such as The Cancer Genome Atlas, TCGA), and validation studies (e.g., protein and functional analyses) to assess GPCRs in human tumors, cancer cells and stromal cells (cancer-associated fibroblasts, CAFs) in the tumor microenvironment. Pancreatic ductal adenocarcinoma (PDAC) tumors and cells and pancreatic CAFs (PCAFs) have been a major focus of our efforts. We find that PDAC cells and PCAFs express >75 different GPCRs, including many orphan GPCRs (receptors without known physiologic agonists) and that numerous GPCRs have much higher expression than in normal precursor cells (pancreatic ductal epithelial cells for PDAC cells and pancreatic stellate cells and fibroblasts for PCAFs). This presentation will review general concepts regarding GPCRs, their signaling and actions and will provide attendees with information regarding GPCRs with higher expression in cancer cells and cells of the tumor microenvironment, in particular CAFs. Findings will be presented related to GPCRs with increased expression in PDAC cells and PCAFs and that appear to contribute to the malignant phenotype. Such GPCRs may be novel biomarkers and therapeutic targets, including for pancreatic cancer, which is predicted to be the second leading cause of cancer death by 2020 and thus has an unmet need for safe and effective therapeutics.

 Read Less
ssclaas=parallelprlval=1Array ( [343] => 1 [6] => 1 )
11:35
Biophysics Guided Drug Discovery Strategies for Oncology Targets
 
Maurizio  Pellecchia
Maurizio Pellecchia
Professor of Biomedical Sciences
University of California, Riverside
About Speaker: Dr. Pellecchia is a chemical biologist with a strong background in pharmaceutical chemistry, biophysics and translational medicine. He trained at the University of Naples (Italy) where he obtained a MS in Organic Chemistry and a Ph.D. in Pharmaceutic... Read Full Bio 
 
 
Maurizio  Pellecchia
Maurizio Pellecchia
Professor of Biomedical Sciences
University of California, Riverside
 
About Speaker:

Dr. Pellecchia is a chemical biologist with a strong background in pharmaceutical chemistry, biophysics and translational medicine. He trained at the University of Naples (Italy) where he obtained a MS in Organic Chemistry and a Ph.D. in Pharmaceutical Sciences, at the ETH-Zurich (working with 2002 Nobel Laureate Prof. Dr. Kurt Wüthrich) and the University of Michigan. Prior to his recruitment in 2002 at the Burnham Institute for Medical Research as Associate Professor, he spent a few years in the pharmaceutical industry. He has served on the faculty of the now Sanford Burnham Prebys medical Discovery Institute for 14 years where he also served as the Associate Director for Translational Research for the Institute’s NCI designated Cancer Center.

Since 2015 he is a Professor of Biomedical Sciences at the University of California at Riverside, School of Medicine and I hold the Daniel Hays endowed Chair in Cancer Research. In addition is the Director of the Center for Molecular and Translational Medicine at UCR. His research is at the forefront of academic drug discovery andchemical biology initiatives. His goals are to support target identification and validation studies in oncology, neurodegenerative, and infectious diseases. The laboratory focuses primarily on the development of innovative pharmacological agents and subsequently apply such agents in target validation studies using cellular and animal models, both internally and via collaborations. Central to these activities are the developing and the application of novel methods and strategies to drug discovery and translational medicine.

 
Abstract: The advances that the fields of cell ...Read More 

The advances that the fields of cell and systems biology made in the past two decades clearly identify protein-protein interactions (PPIs) as the largest class of possible therapeutic targets. Nonetheless, these targets are generally deemed undruggable or at the least very challenging, in that low molecular weight antagonists capable of disrupting the interactions with sufficient potency are not easily identified or designed. We have recently proposed a novel approach, termed HTS by NMR, in which the principles of positional scanning combinatorial chemistry and fragment-based drug design are combined with protein-NMR spectroscopy to iteratively identify and optimize PPIs antagonists from collections of >100,000 compounds. In addition, I will also illustrate a novel method aimed at rapidly scan the thermodynamics of binding of test molecules for a given target in POS libraries (HTS by DH) using isothermal titration calorimetry (ITC) measurements. The benefits of this lecture will include reviewing the most recent advances of the these novel methods and providing examples of their implementations that led to the identification of several pharmacological tools and drug candidates in oncology and possibly other disease areas.

 Read Less
11:35
Fit-For-Purpose Biomarker Assay Validation: Immune Monitoring of Tumor Microenvironment
 
Chetan  Deshpande
Chetan Deshpande
Senior Manager-Biomarker Assay Specialist
Pfizer
About Speaker: ... Read Full Bio 
 
 
Chetan  Deshpande
Chetan Deshpande
Senior Manager-Biomarker Assay Specialist
Pfizer
 
About Speaker:
 
Abstract: Evaluating multiple immune-biomarkers...Read More 

Evaluating multiple immune-biomarkers may provide an accurate and comprehensive assessment of the tumor microenvironment. High-throughput technologies including NGS based assays have been used extensively to identify potential biomarkers to differentiate these tumors by the phenotype and function of immune cells. Of these assays, IHC and NGS based B/T cell receptor repertoire can be used to identify presence of immune cells in tumor microenvironment which have been shown to correlate with response to various immunotherapies. The present work was conducted to perform fit-for-purpose validation of TCR sequencing assay by Adaptive on NSCLC FFPE samples and determine its concordance to IHC based CD3 counting.

 Read Less
ssclaas=parallelprlval=1Array ( [343] => 1 [6] => 1 )
12:00
Receptor Tyrosine Kinase-Interactomes, Drug Action & Genome-Informed Medicine
 
Igor Stagljar
Igor Stagljar
Professor, Donnelly Centre, Department of Molecular Genetics, Department of Biochemistry
University of Toronto
About Speaker: Igor Stagljar is a highly-accomplished mid-career scientist and a Professor in the Departments of Biochemistry and Molecular Genetics at the Donnelly Centre in the University of Toronto, Canada. He received his Ph.D. in Molecular Biology from ETH Zur... Read Full Bio 
 
 
Igor Stagljar
Igor Stagljar
Professor, Donnelly Centre, Department of Molecular Genetics, Department of Biochemistry
University of Toronto
 
About Speaker:

Igor Stagljar is a highly-accomplished mid-career scientist and a Professor in the Departments of Biochemistry and Molecular Genetics at the Donnelly Centre in the University of Toronto, Canada. He received his Ph.D. in Molecular Biology from ETH Zurich in Switzerland. His postdoctoral fellowship was at the University of Zurich, where he studied RNA transcription and DNA repair. In addition, Igor was a visiting scientist at the University of Washington in Seattle with Stan Fields, the inventor of the yeast two-hybrid technology. Igor was Assistant Professor at the University of Zurich from 2002-2005, Associate Professor at the University of Toronto since 2005, and Professor since 2010. Amongst his most significant scientific achievements to date are the elucidation of functions of various membrane proteins involved in human health and disease. He is currently involved in major proteomics projects to map how integral membrane proteins interact to produce either healthy or diseased cells. To that end, his lab is using high-throughput interactive proteomics, genetic, and biochemical tools to understand how cell signaling and membrane transport pathways control cell behavior in normal and disease cells.

Igor is the author of more than 100 PubMed cited scientific papers and is the recipient of several national and international science awards, the most recent one being “The 2015 Inventor of the Year” award. He is a member of the Editorial Board of Journal of Molecular Biology, Molecular Systems Biology, BioTechniques, Molecular Genetics and Genomics, BMC Biotechnology, and Biochemical and Biophysical Research Communications (BBRC). Lastly, he is a co-founder of Dualsystems Biotech Inc., one of the world-leading companies in the field of interactive proteomics, and has recently co-founded a new Toronto-based biotech start-up company named “ProteinNetwork Therapeutix (PN-Tx)”.

 
Abstract: During tumor progression, cancer cell...Read More 

During tumor progression, cancer cells acquire characteristic features, due to signaling pathways that significantly differ compared to normal cells. These pathways involve numerous membrane proteins that transmit signals via tightly regulated protein-protein interactions (PPIs), resulting in conversion of signals into a biological response. Understanding how these signaling networks function in vivo and how they are altered in cancer represents a major scientific challenge crucial to the development of new cancer therapies. However, since membrane proteins are extremely difficult to study using current genomics technologies due to their complex biochemical features, research into this area has lagged behind, with membrane proteins screened to a significantly lower degree than other protein classes.

During my talk, I will report on our previously developed cell based high-throughput proteomics screening technology, called the Mammalian Membrane Two-Hybrid (MaMTH) assay and its application to dissect signaling pathways in normal and cancer cells. In addition, I will discuss how our recent application of MaMTH to various human Receptor Tyrosine Kinases (RTKs), an important family of membrane proteins involved in the variety of cell signaling processes, identified several novel therapeutically important interactors of these RTKs of a therapeutical importance. Lastly, I will also demonstrate how MaMTH can efficiently be used as a drug discovery assay for identification of inhibitory compounds that change the phosphorylation status of the human Epidermal Growth Factor Receptor (EGFR) in the context of living cells and in the low nanomolar range, an advance which may open up a whole new approach to drug development and lead to more effective treatments for lung cancer patients.

 Read Less
12:00
Expanding Role of CROs in the Era of Immuno-Oncology: From Bench to Bedside
 
Rita  Shaknovich
Rita Shaknovich
CMO
Cancer Genetics Inc
About Speaker: I am a physician scientist with strong interests in cancer biology and translational research. My clinical expertise is in Hematopathology with the focus on Hematologic malignancies. My research training was focused on cancer in general and on hemato... Read Full Bio 
 
 
Rita  Shaknovich
Rita Shaknovich
CMO
Cancer Genetics Inc
 
About Speaker:

I am a physician scientist with strong interests in cancer biology and translational research. My clinical expertise is in Hematopathology with the focus on Hematologic malignancies. My research training was focused on cancer in general and on hematologic malignancies in particular from the time of my PhD, investigating function of PLZF-RAR fusion protein in Acute Promyelocytic Leukemia. I have extensive experience in human and mouse pathology, assessment of mouse cancer models, experimental hematology and immunology. My laboratory in WCMC focused on epigenetics of normal B cell development and lymphomagenesis. We utilized cell lines, primary lymphomas and mouse models to investigate epigenetic changes that take place during B cell ontogeny and neoplastic transformation of normal B cells into lymphomas. We successfully utilized many experimental and computational tools that allow genome-wide profiling of DNA methylation and gene expression, like ERRBS, CHIP-seq, RNA-seq, exome and whole genome sequencing among many others. My current role as a Chief Medical Officer at Cancer Genetics Inc is to identify areas of greatest unmet need in cancer diagnostics, to adopt newest technologies and to develop novel tools that would address those needs. We collaborate with leading national and international researchers and institutions to accomplish these goals.

 
Abstract: Key points to be covered: ...Read More 

Key points to be covered:

  • pre-clinical and clinical discovery 
  • adaptation of biomarker testing across methodologies
  • clinical delivery of  FDA-approved tests
 Read Less
ssclaas=mixsessionprlval=1Array ( [6] => 1 )
12:25
Lunch on Your Own
ssclaas=parallelprlval=1Array ( [343] => 1 [6] => 1 )
Oncology Partnering & Deal-Making 2017
Partnering between Pharma, Biotech, Academic Groups and CROs to Advance Research
Moderator: Chris Meda, IncellDx
2:00
Strategic Externalization as a Basis for Novel Deal Structures Between Pharma and Biotech
 
Casey Logan
Casey Logan
Chief Business Officer
TRACON Pharmaceuticals
About Speaker: Mr. Logan joined TRACON as Chief Business Officer in February 2013. Prior to joining TRACON, Mr. Logan led corporate development efforts at RuiYi, Inc. (formerly Anaphore) including establishment of the company’s operations in Shanghai, China. From... Read Full Bio 
 
 
Casey Logan
Casey Logan
Chief Business Officer
TRACON Pharmaceuticals
 
About Speaker:

Mr. Logan joined TRACON as Chief Business Officer in February 2013. Prior to joining TRACON, Mr. Logan led corporate development efforts at RuiYi, Inc. (formerly Anaphore) including establishment of the company’s operations in Shanghai, China. From 2007 to 2010, Mr. Logan led corporate development and strategic planning efforts at Anadys Pharmaceuticals (acquired by Roche). From 2001 to 2007, he was with Eli Lilly and Company in Indianapolis, IN, in the corporate business development group. During his career, Mr. Logan has led transactions in both in-licensing and out-licensing of assets across a range of therapeutic areas, including the creation of two startup companies. Prior to Lilly, Mr. Logan was an officer in the US Naval Nuclear Propulsion Program. Mr. Logan received his M.B.A. from the Kellogg School of Management at Northwestern University and B.S.E. in Chemical Engineering from the University of Michigan.

 
Abstract: Large pharmaceutical companies may la...Read More 

Large pharmaceutical companies may lack the resources to fully develop their deep pipelines, with the result being lost opportunities to maximize the patent life of investigational agents, especially small molecules.  Recent pipeline culling has been reported by Eli Lilly Oncology and others which reflects, in part, the high cost of outsourcing drug development to CROs. Certain biotechnology companies have developed internal product development platforms that manage CMC regulatory, clinical regulatory and clinical operations/data management at costs far less than those typically charged by a CRO.  These platforms provide a resource for pharmaceutical companies interested in strategic externalization, whereby assets are licensed to biotechnology companies, with rights of reacquisition or negotiation retained by the pharmaceutical company.  These types of strategic externalization alliances can accelerate timelines and create value for both partners. One example of this collaboration is a deal between Janssen and TRACON Pharma for two assets in September 2016, which will be profiled in detail.

 Read Less
Complementary & Companion Diagnostics in Oncology 2017
Case Studies for Development and Commercialization
Moderator: Kamala Maddali, Cancer Genetics, Inc.
2:00
Embarking on Rx/CDx Co-Development - How to Get to the Happy End (Concurrent Approvals)
 
Luigi  Catanzariti
Luigi Catanzariti
Principal and Founder
Catanzariti & Associates
About Speaker: Luigi Catanzariti, Ph.D., is the founder and principal of Catanzariti & Associates, a Boston-based private group specializing in technical, regulatory and strategic consulting services in the emerging field of precision medicine, oncology biomark... Read Full Bio 
 
 
Luigi  Catanzariti
Luigi Catanzariti
Principal and Founder
Catanzariti & Associates
 
About Speaker:

Luigi Catanzariti, Ph.D., is the founder and principal of Catanzariti & Associates, a Boston-based private group specializing in technical, regulatory and strategic consulting services in the emerging field of precision medicine, oncology biomarkers, and companion diagnostics. From 2009-2016 he was an Executive Director at NOVARTIS oncology in Cambridge, Massachusetts. In this role, he was responsible for the integrated companion diagnostic strategy/execution of various oncology drug development programs (Ceritinib/Zykadia, Mekinist-Tafinlar, Sonidegib - among others). Zykadia/Ceritinib obtained in 2017 first-line approval (FDA/EMEA) in NSCLC based on a patient selection strategy implemented for the  ASCEND-4 trial.  Before, he held key executive roles at IPSEN (Paris), PYROSEQUENCING (Boston) and bioMerieux (Lyon). He is also author/co-author of numerous international diagnostic and biomarker patents.

 
Abstract: Precision medicine requires therapeut...Read More 

Precision medicine requires therapeutic and diagnostic co-development. Both drug and diagnostic development processes have their own rules and regulations (NDA and PMA). This co-dependency requires significant adjustments by what can be considered quintessentially clinical (Rx) and technical (Dx) development development cultures. Although Rx/CDx partners typically share the goal of concurrent NDA and PMA registrations, priorities are often not aligned. The CDx may, if not carefully considered in the overall plan, delay the registration of the drug if its role is underestimated in both operational and strategic planning.

 Read Less
ssclaas=parallelprlval=1Array ( [343] => 1 [6] => 1 )
2:25
The Path to Market: Commercializing Innovative Technologies
 
Aaron Miscenich
Aaron Miscenich
President
New Orleans BioInnovation Center
About Speaker: Aaron Miscenich has been the President & CEO of the New Orleans BioInnovation Center since 2004.  With an emphasis on entrepreneurship in the life sciences, the BioInnovation Center is a $48 million LEED Gold business incubator, focused primaril... Read Full Bio 
 
 
Aaron Miscenich
Aaron Miscenich
President
New Orleans BioInnovation Center
 
About Speaker:

Aaron Miscenich has been the President & CEO of the New Orleans BioInnovation Center since 2004.  With an emphasis on entrepreneurship in the life sciences, the BioInnovation Center is a $48 million LEED Gold business incubator, focused primarily on the local commercialization of university technologies.

Aaron Miscenich also manages New Orleans BioFund, a $2.4 million evergreen capital source for the regional life science industry. Miscenich oversees the fund’s activity in equity investments, alternative finance/mezzanine lending, and senior debt transactions for start-ups and emerging companies.

From 2011 to 2015 Miscenich was selected to serve as interim Executive Director of the Louisiana Cancer Research Center (LCRC), a New Orleans-based research collaborative between LSU Health Science Center, Tulane University, Xavier University, and the Ochsner Health System.  With the mission of establishing the first National Cancer Institute designated institution in Louisiana, the LCRC now operates from a 170,000 square foot laboratory facility in the heart of the New Orleans' downtown research and clinical community. 

Miscenich is currently the Chairperson of LouisianaBIO, the state affiliation the Biotechnology Industry Organization (BIO) and serves on the board of the Association of University Research Parks (AURP).

Miscenich holds a B.S. in Physics with a minor in Mathematics from the University of New Mexico and an M.B.A. in Finance and General Management from Tulane University.

 
Abstract: It can take a dozen years and hundred...Read More 

It can take a dozen years and hundreds of millions of dollars for a new drug to find its way to market.  There are world changing technologies being developed in labs worldwide that face incredible hurdles in their transformation into products.  Research institutions are looking more and more toward entrepreneurship as a way to find financial support for their ongoing work.  However, putting together the infrastructure necessary to create viable companies can be challenging.  This session will speak about how a research can approach the commercialization process and what considerations need to addressed as the product moves toward the market.

 Read Less
2:25
Isolation of New Cancer Drug Targets Using an Innovative Biomolecule Extraction Technology
 
Saikat Nandi
Saikat Nandi
Senior Research Associate
Cold Spring Harbor Laboratory
About Speaker: Dr. Saikat Nandi is a Senior Research Associate at the Cold Spring Harbor Laboratory (CSHL) and Business Development Consultant for the Long Island Bioscience Hub (LIBH), an NIH-designated and one of only three Research Evaluation and Commercializati... Read Full Bio 
 
 
Saikat Nandi
Saikat Nandi
Senior Research Associate
Cold Spring Harbor Laboratory
 
About Speaker:

Dr. Saikat Nandi is a Senior Research Associate at the Cold Spring Harbor Laboratory (CSHL) and Business Development Consultant for the Long Island Bioscience Hub (LIBH), an NIH-designated and one of only three Research Evaluation and Commercialization Hub (REACH) facilities in the nation. Dr. Nandi also serves as an advisor to Salus Discovery, a start-up from the University of Wisconsin-Madison and Program Director for GTCbio Cancer Therapeutics and Partnering Summit. Dr. Nandi has over 10 years of experience in oncology and drug discovery and over 4 years of experience in technology commercialization and business development through his involvement in the organizations and financially successful start-up companies. Dr. Nandi received his D.Phil. (PhD) from Oxford University and has served as an Editor and Reviewer for over a dozen international scientific journals.

1
ssclaas=parallelprlval=2Array ( [343] => 4 [6] => 4 )
Array ( [5049] => Array ( [sheduleid] => 5049 [new_session] => 1 [single_conf] => 0 [cfid] => 343 [schedule_type] => speakerslot [prev] => 1506608700 [next] => 1506613200 )[5050] => Array ( [sheduleid] => 5050 [new_session] => 0 [single_conf] => 0 [cfid] => 343 [schedule_type] => speakerslot [prev] => 1506608700 [next] => 1506613200 )[5051] => Array ( [sheduleid] => 5051 [new_session] => 0 [single_conf] => 0 [cfid] => 343 [schedule_type] => speakerslot [prev] => 1506608700 [next] => 1506613200 )[5244] => Array ( [sheduleid] => 5244 [new_session] => 1 [single_conf] => 0 [cfid] => 6 [schedule_type] => speakerslot [prev] => 1506608700 [next] => 1506613200 )[5450] => Array ( [sheduleid] => 5450 [new_session] => 0 [single_conf] => 0 [cfid] => 6 [schedule_type] => speakerslot [prev] => 1506608700 [next] => 1506613200 )[5453] => Array ( [sheduleid] => 5453 [new_session] => 0 [single_conf] => 0 [cfid] => 6 [schedule_type] => speakerslot [prev] => 1506608700 [next] => 1506613200 )[6112] => Array ( [sheduleid] => 6112 [new_session] => 0 [single_conf] => 0 [cfid] => 6 [schedule_type] => speakerslot [prev] => 1506608700 [next] => 1506613200 )[6113] => Array ( [sheduleid] => 6113 [new_session] => 0 [single_conf] => 0 [cfid] => 343 [schedule_type] => speakerslot [prev] => 1506608700 [next] => 1506613200 ))
2:50
Panel Discussion: Partnering between Pharma, Biotech, Academic Groups and CROs to Advance Research
Moderator:
Lesley  Stolz
Lesley Stolz
Head of JLABS California
Johnson & Johnson Innovation
 
Lesley  Stolz
Lesley Stolz
Head of JLABS California
Johnson & Johnson Innovation
 
About Speaker:

Lesley Stolz, PhD, fosters Johnson & Johnson’s external R&D engine and supports the innovation community by leading the Johnson & Johnson Innovation, JLABS business on the West Coast. She has 20 years of business and corporate development experience working for companies that have been both technology platform and therapeutics focused. Previously, she was Senior Director of Transactions negotiating partnering deals for Johnson & Johnson Innovation at the California Innovation Center. Prior to joining Johnson & Johnson Innovation, she held executive positions with BioTime, Inc., Sutro Biopharma, Inc., and Sunesis Pharmaceuticals where she was responsible for corporate strategy, fundraising and all aspects of partnering. Earlier in her career, she served as Senior Director, Business Development for Aerovance, Inc. and for GPC Biotech AG in Munich, Germany from 2002 to 2006. She also served in senior management positions at Cell Genesys, Discovery Partners International and Axys Pharmaceuticals. Dr. Stolz received her Ph.D. in chemistry, and conducted postdoctoral research at Harvard Medical School’s Department of Biochemistry and Molecular Pharmacology.

Panelists:
Casey Logan
Casey Logan
Chief Business Officer
TRACON Pharmaceuticals
 
Casey Logan
Casey Logan
Chief Business Officer
TRACON Pharmaceuticals
 
About Speaker:

Mr. Logan joined TRACON as Chief Business Officer in February 2013. Prior to joining TRACON, Mr. Logan led corporate development efforts at RuiYi, Inc. (formerly Anaphore) including establishment of the company’s operations in Shanghai, China. From 2007 to 2010, Mr. Logan led corporate development and strategic planning efforts at Anadys Pharmaceuticals (acquired by Roche). From 2001 to 2007, he was with Eli Lilly and Company in Indianapolis, IN, in the corporate business development group. During his career, Mr. Logan has led transactions in both in-licensing and out-licensing of assets across a range of therapeutic areas, including the creation of two startup companies. Prior to Lilly, Mr. Logan was an officer in the US Naval Nuclear Propulsion Program. Mr. Logan received his M.B.A. from the Kellogg School of Management at Northwestern University and B.S.E. in Chemical Engineering from the University of Michigan.

Gregory Naeve
Gregory Naeve
Chief Business Officer
Bellicum Pharmaceuticals
 
Gregory Naeve
Gregory Naeve
Chief Business Officer
Bellicum Pharmaceuticals
 
About Speaker:
Aaron Miscenich
Aaron Miscenich
President
New Orleans BioInnovation Center
 
Aaron Miscenich
Aaron Miscenich
President
New Orleans BioInnovation Center
 
About Speaker:

Aaron Miscenich has been the President & CEO of the New Orleans BioInnovation Center since 2004.  With an emphasis on entrepreneurship in the life sciences, the BioInnovation Center is a $48 million LEED Gold business incubator, focused primarily on the local commercialization of university technologies.

Aaron Miscenich also manages New Orleans BioFund, a $2.4 million evergreen capital source for the regional life science industry. Miscenich oversees the fund’s activity in equity investments, alternative finance/mezzanine lending, and senior debt transactions for start-ups and emerging companies.

From 2011 to 2015 Miscenich was selected to serve as interim Executive Director of the Louisiana Cancer Research Center (LCRC), a New Orleans-based research collaborative between LSU Health Science Center, Tulane University, Xavier University, and the Ochsner Health System.  With the mission of establishing the first National Cancer Institute designated institution in Louisiana, the LCRC now operates from a 170,000 square foot laboratory facility in the heart of the New Orleans' downtown research and clinical community. 

Miscenich is currently the Chairperson of LouisianaBIO, the state affiliation the Biotechnology Industry Organization (BIO) and serves on the board of the Association of University Research Parks (AURP).

Miscenich holds a B.S. in Physics with a minor in Mathematics from the University of New Mexico and an M.B.A. in Finance and General Management from Tulane University.

Array ( [5049] => Array ( [sheduleid] => 5049 [new_session] => 1 [single_conf] => 0 [cfid] => 343 [schedule_type] => speakerslot [prev] => 1506608700 [next] => 1506613200 )[5050] => Array ( [sheduleid] => 5050 [new_session] => 0 [single_conf] => 0 [cfid] => 343 [schedule_type] => speakerslot [prev] => 1506608700 [next] => 1506613200 )[5051] => Array ( [sheduleid] => 5051 [new_session] => 0 [single_conf] => 0 [cfid] => 343 [schedule_type] => speakerslot [prev] => 1506608700 [next] => 1506613200 )[5244] => Array ( [sheduleid] => 5244 [new_session] => 1 [single_conf] => 0 [cfid] => 6 [schedule_type] => speakerslot [prev] => 1506608700 [next] => 1506613200 )[5450] => Array ( [sheduleid] => 5450 [new_session] => 0 [single_conf] => 0 [cfid] => 6 [schedule_type] => speakerslot [prev] => 1506608700 [next] => 1506613200 )[5453] => Array ( [sheduleid] => 5453 [new_session] => 0 [single_conf] => 0 [cfid] => 6 [schedule_type] => speakerslot [prev] => 1506608700 [next] => 1506613200 )[6112] => Array ( [sheduleid] => 6112 [new_session] => 0 [single_conf] => 0 [cfid] => 6 [schedule_type] => speakerslot [prev] => 1506608700 [next] => 1506613200 )[6113] => Array ( [sheduleid] => 6113 [new_session] => 0 [single_conf] => 0 [cfid] => 343 [schedule_type] => speakerslot [prev] => 1506608700 [next] => 1506613200 ))
2:50
Panel Discussion: Companion Diagnostics Strategies in ImmunoOncology
Moderator:
Kamala  Maddali
Kamala Maddali
Vice President, Biopharm Collaborations and Companion Diagnostics
Cancer Genetics, Inc.
 
Kamala  Maddali
Kamala Maddali
Vice President, Biopharm Collaborations and Companion Diagnostics
Cancer Genetics, Inc.
 
About Speaker:

Dr. Maddali is currently Vice President, Biopharma Collaborations, Market Development and Companion Diagnostics at Cancer Genetics Inc. In addition, Dr. Maddali is the Vice Chair of the Philadelphia Chapter of Women in Bio. She is also a Scientific Advisory Member for International Cancer Advocacy Network. Her background includes time at Quest Diagnostics, Quintiles and Merck Schering Plough in the arena of biomarkers and companion diagnostics. Dr. Maddali holds a Ph.D. in Pharmacology from University of Missouri-Columbia and a DVM from Acharya N.G. Ranga Agricultural University in India. Dr. Maddali loves to travel with her family which includes her husband, Vamsi and son, Venkat. She enjoys music and watching cartoons at her leisure and engaging in many non-profit activities to create cancer awareness.

Panelists:
Saikat Nandi
Saikat Nandi
Senior Research Associate
Cold Spring Harbor Laboratory
 
Saikat Nandi
Saikat Nandi
Senior Research Associate
Cold Spring Harbor Laboratory
 
About Speaker:

Dr. Saikat Nandi is a Senior Research Associate at the Cold Spring Harbor Laboratory (CSHL) and Business Development Consultant for the Long Island Bioscience Hub (LIBH), an NIH-designated and one of only three Research Evaluation and Commercialization Hub (REACH) facilities in the nation. Dr. Nandi also serves as an advisor to Salus Discovery, a start-up from the University of Wisconsin-Madison and Program Director for GTCbio Cancer Therapeutics and Partnering Summit. Dr. Nandi has over 10 years of experience in oncology and drug discovery and over 4 years of experience in technology commercialization and business development through his involvement in the organizations and financially successful start-up companies. Dr. Nandi received his D.Phil. (PhD) from Oxford University and has served as an Editor and Reviewer for over a dozen international scientific journals.

Luigi  Catanzariti
Luigi Catanzariti
Principal and Founder
Catanzariti & Associates
 
Luigi  Catanzariti
Luigi Catanzariti
Principal and Founder
Catanzariti & Associates
 
About Speaker:

Luigi Catanzariti, Ph.D., is the founder and principal of Catanzariti & Associates, a Boston-based private group specializing in technical, regulatory and strategic consulting services in the emerging field of precision medicine, oncology biomarkers, and companion diagnostics. From 2009-2016 he was an Executive Director at NOVARTIS oncology in Cambridge, Massachusetts. In this role, he was responsible for the integrated companion diagnostic strategy/execution of various oncology drug development programs (Ceritinib/Zykadia, Mekinist-Tafinlar, Sonidegib - among others). Zykadia/Ceritinib obtained in 2017 first-line approval (FDA/EMEA) in NSCLC based on a patient selection strategy implemented for the  ASCEND-4 trial.  Before, he held key executive roles at IPSEN (Paris), PYROSEQUENCING (Boston) and bioMerieux (Lyon). He is also author/co-author of numerous international diagnostic and biomarker patents.

Jill  Stefanelli
Jill Stefanelli
Senior Director of Diagnostic Development
ArcherDX, INC.
 
Jill  Stefanelli
Jill Stefanelli
Senior Director of Diagnostic Development
ArcherDX, INC.
 
About Speaker:
ssclaas=mixsessionprlval=1Array ( [6] => 1 )
3:40
Afternoon Networking Break
ssclaas=parallelprlval=0Array ( [6] => 4 )
Round Table Discussions

Array ( [5694] => Array ( [sheduleid] => 5694 [new_session] => 1 [single_conf] => 0 [cfid] => 6 [schedule_type] => speakerslot [prev] => 1506613200 [next] => 1506618000 )[5698] => Array ( [sheduleid] => 5698 [new_session] => 0 [single_conf] => 0 [cfid] => 6 [schedule_type] => speakerslot [prev] => 1506613200 [next] => 1506618000 )[5699] => Array ( [sheduleid] => 5699 [new_session] => 0 [single_conf] => 0 [cfid] => 6 [schedule_type] => speakerslot [prev] => 1506613200 [next] => 1506618000 )[5990] => Array ( [sheduleid] => 5990 [new_session] => 0 [single_conf] => 0 [cfid] => 6 [schedule_type] => speakerslot [prev] => 1506613200 [next] => 1506618000 ))
4:00
Round Table 1: EOP2 Regulatory Considerations Relating to Innovative Clinical Trial Designs, Innovative Business Development Approaches
Suzanne  Benedict
Suzanne Benedict
Vice President of Regulatory Affairs
TRACON Pharmaceuticals
 
Suzanne  Benedict
Suzanne Benedict
Vice President of Regulatory Affairs
TRACON Pharmaceuticals
 
About Speaker:

Ms. Benedict joined TRACON Pharmaceuticals as the Director of Regulatory Affairs in 2007 and was promoted to Vice President of Regulatory Affairs in January 2014. Ms. Benedict previously held positions in Regulatory Chemistry, Manufacturing and Controls (CMC) at Pfizer, Inc. and Amylin Pharmaceuticals, Inc. At Pfizer, she led the Regulatory CMC activities for the approval of Viracept® Tablets, 625 mg and played a key role in the global approvals for Macugen®. She began her pharmaceutical career at Agouron Pharmaceuticals in Medicinal Chemistry synthesizing VEGF inhibitors. Ms. Benedict has led the Regulatory CMC activities on chemical and pharmaceutical development teams from compound identification through commercialization and has experience with small molecule, peptide, oligonucleotide and protein products spanning a wide range of therapeutic areas. Ms. Benedict received a B.A. from the University of California, Santa Barbara and a M.S. in Chemistry from San Diego State University.

Round Table 2: Novel Immuno-Oncology Targets
Rita  Shaknovich
Rita Shaknovich
CMO
Cancer Genetics Inc
 
Rita  Shaknovich
Rita Shaknovich
CMO
Cancer Genetics Inc
 
About Speaker:

I am a physician scientist with strong interests in cancer biology and translational research. My clinical expertise is in Hematopathology with the focus on Hematologic malignancies. My research training was focused on cancer in general and on hematologic malignancies in particular from the time of my PhD, investigating function of PLZF-RAR fusion protein in Acute Promyelocytic Leukemia. I have extensive experience in human and mouse pathology, assessment of mouse cancer models, experimental hematology and immunology. My laboratory in WCMC focused on epigenetics of normal B cell development and lymphomagenesis. We utilized cell lines, primary lymphomas and mouse models to investigate epigenetic changes that take place during B cell ontogeny and neoplastic transformation of normal B cells into lymphomas. We successfully utilized many experimental and computational tools that allow genome-wide profiling of DNA methylation and gene expression, like ERRBS, CHIP-seq, RNA-seq, exome and whole genome sequencing among many others. My current role as a Chief Medical Officer at Cancer Genetics Inc is to identify areas of greatest unmet need in cancer diagnostics, to adopt newest technologies and to develop novel tools that would address those needs. We collaborate with leading national and international researchers and institutions to accomplish these goals.

Round Table 3: Is Comprehensive Genomic Profiling the Future of Precision Medicine or Myth?
Saikat Nandi
Saikat Nandi
Senior Research Associate
Cold Spring Harbor Laboratory
 
Saikat Nandi
Saikat Nandi
Senior Research Associate
Cold Spring Harbor Laboratory
 
About Speaker:

Dr. Saikat Nandi is a Senior Research Associate at the Cold Spring Harbor Laboratory (CSHL) and Business Development Consultant for the Long Island Bioscience Hub (LIBH), an NIH-designated and one of only three Research Evaluation and Commercialization Hub (REACH) facilities in the nation. Dr. Nandi also serves as an advisor to Salus Discovery, a start-up from the University of Wisconsin-Madison and Program Director for GTCbio Cancer Therapeutics and Partnering Summit. Dr. Nandi has over 10 years of experience in oncology and drug discovery and over 4 years of experience in technology commercialization and business development through his involvement in the organizations and financially successful start-up companies. Dr. Nandi received his D.Phil. (PhD) from Oxford University and has served as an Editor and Reviewer for over a dozen international scientific journals.

Round Table 4: When Does Liquid Biopsy Get the Clinical Utility to Replace Archival Tissue in Treatment Decisions
Eric  Lindquist
Eric Lindquist
Vice President of Pharma Business Development
Natera
 
Eric  Lindquist
Eric Lindquist
Vice President of Pharma Business Development
Natera
 
About Speaker:

Eric has over 20 years of experience in the precision medicine space. Eric was trained in cytogenetics but started his commercial career at Abbott Molecular selling the first DNA based FDA approved and cleared companion diagnostic assays to directly to laboratories and clinicians.  Eric has also worked for Johnson and Johnson in their Veridex group enabling pharmaceutical companies to incorporate rare cells into their clinical trials. Eric then worked at Roche where he executed a number of public and non-public companion diagnostic agreements.  Eric also led the Translational Diagnostics team at Asuragen.  While at Asuragen, Eric’s team executed an umbrella agreement with lllumina enabling Asuragen to be the first 3rd party company to have CDx developed FTO on the MiSeq platform.   Eric has also consulted for a significant number of diagnostic and pharmaceutical regarding their companion diagnostic partnership, development, and commercialization strategies and tactics.

ssclaas=mixsessionprlval=1Array ( [6] => 1 )
5:00
Networking Reception & Poster Session
ssclaas=mixsessionprlval=1Array ( [342] => 1 )
Day - 2 Friday, September 29th, 2017
 
7:30
Breakfast with Mentors from Academia & Industry (RSVP only)
ssclaas=mixsessionprlval=1Array ( [342] => 1 )
7:45
Continental Breakfast
ssclaas=parallelprlval=1Array ( [343] => 1 [342] => 1 )
Oncology Partnering & Deal-Making 2017
Oncology Perspectives from Venture Capital and Public Markets
Moderator: Kamala Maddali, Cancer Genetics, Inc.
8:45
The Current State of Public and Venture Funding for Oncology Companies
 
Enoch Kariuki
Enoch Kariuki
Vice President
H.I.G. BioHealth Partners
About Speaker: Enoch is a Vice President at H.I.G. BioHealth Partners, where he focuses on investment opportunities in the life sciences sector. Prior to joining H.I.G., he was a Senior Associate at Leerink Partners, a healthcare focused investment bank. He joined ... Read Full Bio 
 
 
Enoch Kariuki
Enoch Kariuki
Vice President
H.I.G. BioHealth Partners
 
About Speaker:

Enoch is a Vice President at H.I.G. BioHealth Partners, where he focuses on investment opportunities in the life sciences sector. Prior to joining H.I.G., he was a Senior Associate at Leerink Partners, a healthcare focused investment bank. He joined Leerink from UBS where he was an Associate Director in the Global Healthcare Investment Banking Group. At Leerink and UBS, Enoch gained extensive experience advising healthcare companies across the biopharmaceutical, medical devices, diagnostics, healthcare services and information technology sectors on equity capital financings, mergers and acquisitions, leveraged buyouts, and recapitalizations.

Previously, Enoch worked in the pharmaceutical industry as a Post-Doctoral Fellow in the R&D Strategy and Analytics group at Bristol-Myers Squibb and as a Pharmacist at CVS Caremark.

Enoch earned an M.B.A. from the Tuck School of Business at Dartmouth and a Doctor of Pharmacy degree from Texas Southern University.

 
Abstract: Investment in new oncology therapies ...Read More 

Investment in new oncology therapies continues to be one of the most exciting areas of focus for public equities and venture capital investors. According to the IMS Global Oncology Trend Report, over $100 billion is spent annually on cancer therapy. The number of cancer cases is estimated to increase by 70% over the next two decades, and is expected to reach 25 million new cases per year by 2030. This increasing disease burden is a key driver of continuing investment in new cancer therapeutic approaches. However, as recently noted by the American Society of Clinical Oncology (ASCO), the promise of new treatments and breakthroughs in technology has to be balanced against continuing concerns about cost, uncertainty around implementation of health care reform, and the increasing complexity of cancer treatment.

The presentation will focus on key trends in the oncology investment landscape, including a discussion on new technologies such as gene therapy and immunotherapy, venture capital flow into oncology companies, IPO market for oncology companies, strategic M&A oncology landscape, as well as political and cost containment headwinds that are having an impact on the sector.

 Read Less
Cancer Immunotherapy 2017
Precision Medicine and Immunomodulatory Antibodies
Moderator: Yvonne Lin, Genentech-Roche
8:45
Discovery and Early Clinical Development of eFT508, an Activator of Anti-tumor Immune Response
 
Kevin  Webster
Kevin Webster
Sr. Vice President, Cancer Biology
eFFECTOR Therapeutics
About Speaker: Dr. Webster is Sr. Vice President of Cancer Biology at eFFECTOR Therapeutics focused on pioneering the discovery and development of a new class of oncology drugs known as selective translation regulators (STRs). Prior to joining eFFECTOR Dr. Webs... Read Full Bio 
 
 
Kevin  Webster
Kevin Webster
Sr. Vice President, Cancer Biology
eFFECTOR Therapeutics
 
About Speaker:

Dr. Webster is Sr. Vice President of Cancer Biology at eFFECTOR Therapeutics focused on pioneering the discovery and development of a new class of oncology drugs known as selective translation regulators (STRs). Prior to joining eFFECTOR Dr. Webster was Vice President of Oncology Research at AstraZeneca Pharmaceuticals, where he led the oncology discovery organization in Waltham, MA. In this role he served on the global oncology leadership team accountable for science strategy overseeing the delivery of a project portfolio spanning discovery and early clinical development. During his tenure with AstraZeneca he was accountable for building a new drug discovery bioscience organization in the US, as well as spearheading the creation of novel partnerships with academia and biotech organizations. Prior to AstraZeneca, Dr. Webster served as a member of the oncology drug discovery leadership team at Bristol Myers Squibb where he led the cell cycle and apoptosis research areas and delivered multiple discovery research projects from inception through early clinical development. Dr. Webster holds a Ph.D. in Molecular Biophysics and Biochemistry from Yale University where he studied protein-RNA interactions and translational regulation.

 
Abstract: eFT508 is a potent and highly selecti...Read More 

eFT508 is a potent and highly selective inhibitor of MNK1 and MNK2, kinases that function to mediate tumor immune evasion downstream of MEK and MAPK signaling. eFT508 treatment establishes a regulatory program that promotes multiple steps in the cancer immunity cycle including, antigen presentation and T cell priming, expansion of memory T cells, and prevention of T cell exhaustion. eFT508 selectively down regulates the induction of several immunosuppressive mechanisms including IL-10 and the immune checkpoint proteins PD-1, PD-L1, TIM3 and LAG3. Further evaluation of the mechanism of action has demonstrated MNK selectively regulates gene expression at the level of mRNA translational and is dependent on specific sequence elements in the 5’- and 3’-untranslated regions of the mRNA. eFT508 is currently under evaluation as a single agent in two phase 1/2 clinical trials for patients with advanced solid tumors and patients with advanced lymphoma. Upon confirmation of the RP2D a biomarker driven proof of concept study designed to evaluate the immunological mechanism of action of the drug has been initiated. This trial includes mandatory pre- and on-treatment biopsies and will measure markers of immune activation in the tumor and circulating cells. In addition, a phase 2 study evaluating eFT508, alone or in combination with avelumab, a PD-L1 immune checkpoint inhibitor, in microsatellite stable relapsed or refractory CRC patients is planned. This trial also includes mandatory pre- and on-treatment biopsies to evaluate the combined immune effect of eFT508 in combination with checkpoint inhibition. These data will complement and inform future trials evaluating eFT508 in combination with immune checkpoint inhibitors.

 Read Less
1
ssclaas=parallelprlval=2Array ( [343] => 2 [342] => 1 )
Array ( [5246] => Array ( [sheduleid] => 5246 [new_session] => 0 [single_conf] => 0 [cfid] => 342 [schedule_type] => speakerslot [prev] => 1506674700 [next] => 1506677700 )[5949] => Array ( [sheduleid] => 5949 [new_session] => 1 [single_conf] => 0 [cfid] => 343 [schedule_type] => speakerslot [prev] => 1506674700 [next] => 1506677700 )[5950] => Array ( [sheduleid] => 5950 [new_session] => 0 [single_conf] => 0 [cfid] => 343 [schedule_type] => speakerslot [prev] => 1506674700 [next] => 1506677700 ))
9:10
Panel Discussion: Oncology Perspectives from Venture Capital and Public Markets
Enoch Kariuki
Enoch Kariuki
Vice President
H.I.G. BioHealth Partners
 
Enoch Kariuki
Enoch Kariuki
Vice President
H.I.G. BioHealth Partners
 
About Speaker:

Enoch is a Vice President at H.I.G. BioHealth Partners, where he focuses on investment opportunities in the life sciences sector. Prior to joining H.I.G., he was a Senior Associate at Leerink Partners, a healthcare focused investment bank. He joined Leerink from UBS where he was an Associate Director in the Global Healthcare Investment Banking Group. At Leerink and UBS, Enoch gained extensive experience advising healthcare companies across the biopharmaceutical, medical devices, diagnostics, healthcare services and information technology sectors on equity capital financings, mergers and acquisitions, leveraged buyouts, and recapitalizations.

Previously, Enoch worked in the pharmaceutical industry as a Post-Doctoral Fellow in the R&D Strategy and Analytics group at Bristol-Myers Squibb and as a Pharmacist at CVS Caremark.

Enoch earned an M.B.A. from the Tuck School of Business at Dartmouth and a Doctor of Pharmacy degree from Texas Southern University.

Moderator:
Kamala  Maddali
Kamala Maddali
Vice President, Biopharm Collaborations and Companion Diagnostics
Cancer Genetics, Inc.
 
Kamala  Maddali
Kamala Maddali
Vice President, Biopharm Collaborations and Companion Diagnostics
Cancer Genetics, Inc.
 
About Speaker:

Dr. Maddali is currently Vice President, Biopharma Collaborations, Market Development and Companion Diagnostics at Cancer Genetics Inc. In addition, Dr. Maddali is the Vice Chair of the Philadelphia Chapter of Women in Bio. She is also a Scientific Advisory Member for International Cancer Advocacy Network. Her background includes time at Quest Diagnostics, Quintiles and Merck Schering Plough in the arena of biomarkers and companion diagnostics. Dr. Maddali holds a Ph.D. in Pharmacology from University of Missouri-Columbia and a DVM from Acharya N.G. Ranga Agricultural University in India. Dr. Maddali loves to travel with her family which includes her husband, Vamsi and son, Venkat. She enjoys music and watching cartoons at her leisure and engaging in many non-profit activities to create cancer awareness.

Array ( [5246] => Array ( [sheduleid] => 5246 [new_session] => 0 [single_conf] => 0 [cfid] => 342 [schedule_type] => speakerslot [prev] => 1506674700 [next] => 1506677700 )[5949] => Array ( [sheduleid] => 5949 [new_session] => 1 [single_conf] => 0 [cfid] => 343 [schedule_type] => speakerslot [prev] => 1506674700 [next] => 1506677700 )[5950] => Array ( [sheduleid] => 5950 [new_session] => 0 [single_conf] => 0 [cfid] => 343 [schedule_type] => speakerslot [prev] => 1506674700 [next] => 1506677700 ))
9:10
Applications of CD40 Ligand (CD40L) and 4-1BB Ligand (4-1BBL) to Cancer Immunotherapy
 
Richard Kornbluth
Richard Kornbluth
President & Chief Scientific Officer
Multimeric Biotherapeutics
About Speaker: Richard S. Kornbluth, M.D., Ph.D. is President and Chief Scientific Officer of Multimeric Biotherapeutics, Inc., La Jolla, CA, and Professor at the Vaccine Research Institute of San Diego. He trained in tumor biology and immunology at Harvard and The... Read Full Bio 
 
 
Richard Kornbluth
Richard Kornbluth
President & Chief Scientific Officer
Multimeric Biotherapeutics
 
About Speaker:

Richard S. Kornbluth, M.D., Ph.D. is President and Chief Scientific Officer of Multimeric Biotherapeutics, Inc., La Jolla, CA, and Professor at the Vaccine Research Institute of San Diego. He trained in tumor biology and immunology at Harvard and The Scripps Research Institute following which he moved to UC San Diego (UCSD) where he focused on HIV-macrophage interactions and HIV vaccines. While at UCSD as an Associate Professor of Medicine, he developed a novel technology for expressing TNF SuperFamily ligands as soluble, multi-trimer proteins. Multimeric Biotherapeutics was founded to develop this invention and the company has since been supported by grants and contracts from the NCI, NIAID, NIDA, NIDDK, and the DOD. Dr. Kornbluth received his A.B. from Harvard, M.D. from New York Medical College, and Ph.D. from Columbia University.

 
Abstract: CD40L (CD154) and 4-1BBL (CD137L) are...Read More 

CD40L (CD154) and 4-1BBL (CD137L) are TNF SuperFamily (TNFSF) ligands produced as trimeric membrane molecules. However, their corresponding receptors (CD40 and 4-1BB) require clustering beyond the trimer in order to signal. Thus, single trimers are poor stimuli because they cannot produce the necessary clustering. We have solved the receptor clustering problem by creating fusion proteins that contain many TNFSF trimers. As scaffolds for these molecules, we used surfactant protein D (SP-D) to make molecules with 4 trimeric arms (“UltraLigands™”) and ACRP30 (A Complement-Related Protein 30 kD or adiponectin) to make molecules with 2 trimeric arms (“MegaLigands™”). The lead molecule is CD40L which is well known as the key activator of dendritic cell antigen-presentation for the generation of CD8+ T cells, including anti-tumor and anti-viral T cells. Less well known is that CD40L is also a death signal for certain CD40+ tumor cells such as ovarian cancer, breast cancer, and others. Agonistic anti-CD40 antibodies have not been demonstrated to have this cell killing function. We have now shown that multi-trimer CD40L is cytotoxic for ovarian cancer cells in culture, including BRCA1 mutant cells. This opens the possibility of using CD40L as a “one-two punch” against ovarian and other CD40+ cancers: (1) direct cancer cell killing; and (2) generation of CD8+ T cells to clean up residual tumor cells. In separate studies, multi-trimer 4-1BBL was found to stimulate CD8+ T cells and NK cells in vitro, which makes it a valuable tool for adoptive cell therapy (ACT) strategies using TILSs, TCR-transgenic T cells, CAR-T cells, or NK cells. In conclusion, soluble multi-trimer forms of TNFSFs such as CD40L and 4-1BBL have many important applications in cancer immunotherapy.

Benefits:

  • Understanding of the ligation requirements of TNFSF receptors
  • Novel methods for producing multi-trimer TNFSF ligands
  • Role of CD40 as a death receptor for ovarian, breast, and other CD40+ cancers
  • Cell manufacturing uses of soluble 4-1BBL for adoptive cell therapy
 Read Less
9:35
De-Risking Clinical Trials Through Simple Sample Logistics and Moving Immune Monitoring Beyond Challenges of Flow Cytomerty
 
Thomas  Kleen
Thomas Kleen
Executive Vice President, Immune Monitoring
Epiontis
About Speaker: Dr. Kleen is currently Executive VP Immune Monitoring at Epiontis.  Prior he held the position of Director, Business and Technology Development and the function of Director, Assay Development and R&D at CTL, USA He received his Ph.D. in Biology ... Read Full Bio 
 
 
Thomas  Kleen
Thomas Kleen
Executive Vice President, Immune Monitoring
Epiontis
 
About Speaker:

Dr. Kleen is currently Executive VP Immune Monitoring at Epiontis.  Prior he held the position of Director, Business and Technology Development and the function of Director, Assay Development and R&D at CTL, USA He received his Ph.D. in Biology with specialty in Immunology and Virology from the Bayerische Julius-Maximilians-University Würzburg, Bavaria, Germany.  During his studies at Case Western Reserve University in Cleveland, Ohio, he investigated conditions of the human immune system affected by infectious diseases, and in particular the detailed monitoring of immune cell function in patients with human immune deficiency virus (HIV) infections.  He further conducted research on the facilitation of umbilical cord blood stem cell transplantation for immune reconstitution of adult patients with life-threatening hematologic al disorders and malignancies after treatment with full myelo-ablative regimens (http://www.linkedin.com/in/thomasokleen).

His expertise is in the areas of immunology, vaccine and biologic evaluation, immunogenicity and oncology.  One focus is monitoring of Cell Mediated Immunity (CMI) and Bio-markers during immunotherapy, vaccine development and detection of adverse immune reactions during drug development.  He spends significant time educating pharmaceutical entities and governmental agencies about validated, standardized, GLP compliant technologies, which can be deployed today during pre-clinical and clinical trials, for sample logistics and immune monitoring.
Since 2009 Dr. Kleen is member of the SITC-FDA Task Force on Immunotherapy Biomarkers, which focuses on the unique issues related to immunologic monitoring assays as well as novel methodologies for assessing the immune landscape in cancer.

 
Abstract: Immunotherapy with antibody based the...Read More 

Immunotherapy with antibody based therapy is now an established modality in the anticancer arsenal with increased clinical efficacy but little relevance of assessing success by standard pharmacokinetics (PK) and pharmacodynamics (PD). Systemic and intratumoral effects of current and future immunologically target agents must instead be asserted by investigation and refinement of immunological endpoints. The translation of immunological signals to patient outcome and informing clinical trial design and phase 2 and later studies has proven to be challenging in practice. Many of the obstacles to collecting the relevant information is found in clinical site sample logistics and amount of material required. Together with shipping and stability concerns it often has been prohibitive risky and costly to include broad flow cytomerty based monitoring strategies in large phase 2 and specifically phase 3 studies. DNA based monitoring approaches can mitigate most of those obstacles.

 Read Less
ssclaas=mixsessionprlval=1Array ( [342] => 1 )
10:00
Morning Networking Break
ssclaas=parallelprlval=1Array ( [343] => 1 [342] => 1 )
Oncology Partnering & Deal-Making 2017
Technology Transfer & Licensing: Challenges & Opportunities
Moderator: Saikat Nandi, Cold Spring Harbor Laboratory
10:40
Why Can't We Be Friends?
 
Kathleen  Denis
Kathleen Denis
Associate Vice President, Office of Technology Transfer
The Rockefeller University
About Speaker: Managing the intellectual assets of The Rockefeller University in New York City, Dr. Denis works with their elite group of researchers to establish partnerships with industry in order to develop and commercialize technologies for the public good. She... Read Full Bio 
 
 
Kathleen  Denis
Kathleen Denis
Associate Vice President, Office of Technology Transfer
The Rockefeller University
 
About Speaker:

Managing the intellectual assets of The Rockefeller University in New York City, Dr. Denis works with their elite group of researchers to establish partnerships with industry in order to develop and commercialize technologies for the public good. She is a Past President of the Licensing Executives Society USA/Canada (LES), and has served on the Board of Directors of the Association of University Technology Managers (AUTM), the Pennsylvania Biotechnology Association and is a former Chair of the Board of Governors of Certified Licensing Professionals, Inc. Specializing in the management of intellectual assets in the life sciences, she has worked with academic institutions and industry clients to manage intellectual property portfolios, evaluate new technologies, market and license technologies and start new technology-based businesses. Dr. Denis holds a Ph.D. in immunology from the University of Pennsylvania, an M.A. in human genetics from University of Texas and an undergraduate degree in genetics from Cornell University.

 
Abstract: University-Industry relations is a ba...Read More 

University-Industry relations is a balancing game. From two very different cultures, we share some very important goals that can affect human health in a profound way. Working together is ever more important in this world of fast moving scientific discovery. We will try to unravel the needs and wants of these two potential partners so we can understand the most effective ways of working together. “Different” does not need to be a value judgement!

 Read Less
Cancer Immunotherapy 2017
Combination Immunotherapy and Novel Targets
Moderator: Richard Kornbluth, Multimeric Biotherapeutics
10:40
Combination Immunotherapy of Cancer
 
Alan  Epstein
Alan Epstein
Professor of Pathology
Keck School of Medicine of USC
About Speaker: Alan Epstein received his bachelors degree from Wesleyan University and his MD/PhD degrees from Stanford University School of Medicine. His research focuses on various aspects of tumor biology but most recently, on the development of reagents for the... Read Full Bio 
 
 
Alan  Epstein
Alan Epstein
Professor of Pathology
Keck School of Medicine of USC
 
About Speaker:

Alan Epstein received his bachelors degree from Wesleyan University and his MD/PhD degrees from Stanford University School of Medicine. His research focuses on various aspects of tumor biology but most recently, on the development of reagents for the immunotherapy of cancer. In addition, his laboratory is involved in elucidating the host/tumor interaction including the induction and function of suppressor cell populations and methods to reverse their activity in cancer. Over a 34 year career, he has developed several antibodies for the treatment of cancer including Lym-1 for lymphoma therapy and Tumor Necrosis Antibodies that target necrosis in cancer lesions. In addition, he has generated a number of diagnostic antibodies including a human myeloid derived suppressor cell clinical assay for the diagnosis and monitoring of cancer patients. His latest research interests are in the area of genetically engineered T cells for the treatment of solid tumors in patients. He has founded three biotechnology companies and has acted as a consultant to the industry in his field of expertise. Dr. Epstein has over 165 peer reviewed publications and 25 patents on reagents and methods for cancer immunotherapy.

 
Abstract: Immunotherapy is a powerful therapeut...Read More 

Immunotherapy is a powerful therapeutic modality that has great potential for the treatment of cancer. Considering the lack of options which exist for patients with refractory solid tumors, immunotherapy could provide patients with an alternative treatment that may be used in conjunction with existing therapies. Our hypothesis is that successful immunotherapy may require two critical steps for the treatment of solid tumors. First, the immune response that is generated in cancer patients needs to be amplified and involve several different cellular components associated with innate immunity and adaptive immunity. Secondly, negative regulatory mechanisms for suppressing the immune response against self-antigens need to be diminished during the time of tumor immunotherapy. Because of this, we have focused on the delivery of potent immunoregulatory signals that can reverse tolerance and alter the tumor microenvironment to support immunotherapy regimens. Critical to our success has been the use of an antibody targeting approach, designated Tumor Necrosis Therapy (TNT), which utilizes stable intracellular antigens present in all cell types but which are only accessible in dead and/or dying cells. Since tumors contain abundant necrosis, this targeting approach can be used to deliver therapeutic reagents to the core of tumors, a site rich in tumor antigens. The use of this antibody targeting approach in syngeneic tumor models has enabled us to compare the effects of payloads in immunocompetent mice, a requirement for successful immunotherapy. To date, many sets of immunological moieties have been tested in our laboratory including antibody/cytokine, antibody/chemokine, antibody/co-stimulatory molecules, and antibody/TLR agonists. All have shown some degree of success in solid tumor models and several have been shown to have additive or synergistic effects when used together. In this presentation, we will demonstrate the feasibility of these immunotherapeutic reagents for the systemic treatment of different types of tumors using TNT antibodies to provide the foundation for clinical cancer immunotherapy evaluation. In addition, data are presented to uncover how tumors defeat immunity by describing the immune profile of specific murine and human tumors. These biomarker studies are critical for our understanding of which immunotherapeutic approaches are most likely to be effective in individual patients and/or tumor types.

 Read Less
ssclaas=parallelprlval=1Array ( [343] => 1 [342] => 1 )
11:05
Innovative Approaches to Accelerate Commercialization of Academic Inventions
 
Rubén Flores-Saaib
Rubén Flores-Saaib
Director of Commercialization
University of California, San Diego
About Speaker: Ruben earned his doctorate in chemistry and biochemistry at UCLA, and began his career in the San Diego biotechnology industry at BD Biosciences Pharmigen. He has held a variety of positions with increasing responsibility in R&D, marketing, busin... Read Full Bio 
 
 
Rubén Flores-Saaib
Rubén Flores-Saaib
Director of Commercialization
University of California, San Diego
 
About Speaker:

Ruben earned his doctorate in chemistry and biochemistry at UCLA, and began his career in the San Diego biotechnology industry at BD Biosciences Pharmigen. He has held a variety of positions with increasing responsibility in R&D, marketing, business development and technology commercialization. His professional career also includes Biosite (now Inverness), where he helped design, initiate, negotiate and monitor clinical trials; and later joined Chemicon (now Millipore-Sigma), where he managed R&D, worldwide clinical-trial operations, and marketing activities for diagnostic products. While at Millipore-Sigma, Flores also created the world-wide Scientific Collaborations and Business Development group, tasked with working with academic partners across the globe for the development of early-stage academic research.

Most recently, Flores served as Vice President of Business Development and Technology Transfer for the Los Angeles BioMedical Research Institute at Harbor UCLA Medical Center, where he focused on fostering the entrepreneurial ecosystem for startups in Los Angeles.

As Director of Commercialization, Flores oversees all aspects of licensing and company interactions, as well as programs to engage with industry and investment partners. .

 
Abstract: ...Read More 

UC San Diego understands that the best approach to commercialization of academic derived inventions is to allow the business experts do their job.

To that end, UC San Diego has developed simplified approaches to licensing agreements, collaborations with industry and new startup formation which

greatly reduce the economic burden up-front. Come and learn about these new approaches and help us develop better ways to commercialize academic technologies

 Read Less
11:05
ProTIA: Protease Triggered Immune Activators - A Novel Therapeutic Platform for Immunooncologics
 
Ulrich Ernst
Ulrich Ernst
Chief Operating Officer
Amunix
About Speaker: Ulrich Ernst, PhD is the Chief Operating Officer at Amunix. Dr. Ernst has previously held senior level positions with several global biopharmaceutical companies and brings over 25 years of experience in successfully moving products from clinical stag... Read Full Bio 
 
 
Ulrich Ernst
Ulrich Ernst
Chief Operating Officer
Amunix
 
About Speaker:

Ulrich Ernst, PhD is the Chief Operating Officer at Amunix. Dr. Ernst has previously held senior level positions with several global biopharmaceutical companies and brings over 25 years of experience in successfully moving products from clinical stage development to market approval. As VP/Site Head of Alexion’s commercial Rhode Island manufacturing facility, Dr. Ernst led the startup efforts to gain FDA, EMA and rest-of-world site approvals for SOLIRIS®. As Vice-President of Commercial Manufacturing at ZymoGenetics, Dr. Ernst helped create the infrastructure for the commercial manufacturing/medical device enterprise which launched the RECOTHROM® hemostasis franchise. Additionally, Dr. Ernst has held senior operations positions with JNJ and Baxter, where he contributed to the product development and global launches of NATRECOR® and ADVATE®, respectively. Dr. Ernst began his career at Regeneron and Somatogen where he contributed to development efforts on novel protein therapeutics. Dr. Ernst received a B.S. in Chemical Engineering from the University of Minnesota and a Ph.D. in Chemical Engineering from Lehigh University in Pennsylvania. Dr. Ernst is broadly published and is an inventor on several patents.

 
Abstract: In recent years, treatment regimens h...Read More 

In recent years, treatment regimens harnessing the immune system have emerged that have demonstrated improved clinical response for select cancer types. However, the prognosis over the last two decades for patients with advanced solid tumors has not improved much and a significant unmet need remains for new and more effective treatments. Advances to overcome the inherent functional limitations of current immune-based therapies are being developed at Amunix (Mountain View, CA). Amunix has developed a novel class of bispecific T-cell activators with long half-life with the potential to achieve a superior safety profile compared to other previously developed bispecific therapeutic formats. The melding of Amunix’ established XTEN® half-life extension technology with bispecific T cell engagers has yielded a novel class of long-acting, pro-drug, immuno-oncologics under Amunix’ recently unveiled ProTIA technology platform. The design of ProTIA molecules represents a technical enhancement of bispecific scFv therapeutic formats, with the benefits of significantly improved circulatory half-life and enhanced safety profiles. A functional prodrug delivery format has been created by insertion of tumor-specific protease cleavage sites between the active payload and the adjoining XTEN sequence of defined length and sequence, thereby facilitating selective release of the active, bispecific payload in the tumor domain.

 Read Less
ssclaas=parallelprlval=2Array ( [343] => 5 [342] => 1 )
Array ( [5042] => Array ( [sheduleid] => 5042 [new_session] => 0 [single_conf] => 0 [cfid] => 342 [schedule_type] => speakerslot [prev] => 1506683100 [next] => 1506686100 )[5055] => Array ( [sheduleid] => 5055 [new_session] => 1 [single_conf] => 0 [cfid] => 343 [schedule_type] => speakerslot [prev] => 1506683100 [next] => 1506686100 )[5056] => Array ( [sheduleid] => 5056 [new_session] => 0 [single_conf] => 0 [cfid] => 343 [schedule_type] => speakerslot [prev] => 1506683100 [next] => 1506686100 )[5057] => Array ( [sheduleid] => 5057 [new_session] => 0 [single_conf] => 0 [cfid] => 343 [schedule_type] => speakerslot [prev] => 1506683100 [next] => 1506686100 )[5983] => Array ( [sheduleid] => 5983 [new_session] => 0 [single_conf] => 0 [cfid] => 343 [schedule_type] => speakerslot [prev] => 1506683100 [next] => 1506686100 )[6044] => Array ( [sheduleid] => 6044 [new_session] => 0 [single_conf] => 0 [cfid] => 343 [schedule_type] => speakerslot [prev] => 1506683100 [next] => 1506686100 ))
11:30
Panel Discussion: Technology Transfer and Licensing: Challenges and Opportunities
Panelists:
Kathleen  Denis
Kathleen Denis
Associate Vice President, Office of Technology Transfer
The Rockefeller University
 
Kathleen  Denis
Kathleen Denis
Associate Vice President, Office of Technology Transfer
The Rockefeller University
 
About Speaker:

Managing the intellectual assets of The Rockefeller University in New York City, Dr. Denis works with their elite group of researchers to establish partnerships with industry in order to develop and commercialize technologies for the public good. She is a Past President of the Licensing Executives Society USA/Canada (LES), and has served on the Board of Directors of the Association of University Technology Managers (AUTM), the Pennsylvania Biotechnology Association and is a former Chair of the Board of Governors of Certified Licensing Professionals, Inc. Specializing in the management of intellectual assets in the life sciences, she has worked with academic institutions and industry clients to manage intellectual property portfolios, evaluate new technologies, market and license technologies and start new technology-based businesses. Dr. Denis holds a Ph.D. in immunology from the University of Pennsylvania, an M.A. in human genetics from University of Texas and an undergraduate degree in genetics from Cornell University.

Alice Li
Alice Li
Executive Director, Center for Technology Licensing
Cornell University
 
Alice Li
Alice Li
Executive Director, Center for Technology Licensing
Cornell University
 
About Speaker:

Alice Li is the Executive Director of the Center for Technology Licensing (CTL) at Cornell University. She oversees all aspects of technology management, marketing, license negotiation, outreach, and CTL activities to facilitate new venture creation in its services to all Cornell campuses and colleges.

Reflective of its broad research endeavors, Cornell’s inventions range from disciplines such as chemistry, engineering, information technologies, and material science, to medicine, plant science, and veterinary medicine.

Alice has 14 years of experience in university technology transfer. She was the Director of Licensing of the Ithaca office from 2011 to 2014, providing mentorship for licensing professionals in intellectual property protection, license negotiation, and spearheading new commercialization initiatives. Alice joined CTL in 2002 and started with hands-on management of invention portfolios, negotiations of complex deals and engagement with startup companies.

Prior to joining CTL, Alice was an R&D manager at BioArray Solutions, a NJ biotech company in diagnostic and drug discovery. During her five-year tenure there, the company grew from a two-person startup to an enterprise of fifty people. BioArray Solutions was acquired by a publicly traded company in 2008.

Alice obtained her Ph.D. from Cornell University and B.S. from Tsinghua University. She is also an inventor and patent holder. Alice has been a Certified Licensing Professional since 2010.

Michael Arciero
Michael Arciero
Director of Technology Licensing and New Ventures
USC Stevens Center for Innovation
 
Michael Arciero
Michael Arciero
Director of Technology Licensing and New Ventures
USC Stevens Center for Innovation
 
About Speaker:

Michael Arciero, J.D. is the Director of Technology Licensing and New Ventures at the USC Stevens Center for Innovation with over 15 years of experience in academic, foundation, and industry technology transfer. Most recently, Arciero was Interim Director of the University of California, Riverside (UCR) Office of Technology Commercialization where he worked closely with faculty, staff, and students to help identify and commercialize their research. Arciero led the UCR negotiation efforts with a large company which resulted in a significant increase in research funding and the closing of a new license agreement for the commercialization of key technology in the University’s intellectual property portfolio. Prior to UCR, Arciero was counsel for the E.O. Wilson Biodiversity Foundation, and served as a licensing attorney at Diversa Corporation (now BASF), where he focused on licensing the company’s industrial enzymes portfolio and supported the business development groups in monetizing access to their proprietary environmental sequence libraries.

Arciero started his career in biotechnology as a researcher at LXN Corporation (now Johnson & Johnson) where he worked on the development of the first portable diagnostic device for diabetes management that allowed patients to measure both blood glucose and glycated protein (fructosamine).

Arciero earned a Bachelor of Science in Biology from the University of California, San Diego and a J.D. from the University of San Diego School of Law. He is an active member of the Association of University Technology Managers, Licensing Executives Society, Biotechnology Industry Organization and Association of Strategic Alliance Professionals.

Casie Kelly
Casie Kelly
Assistant Director of Licensing
University of California, Irvine
 
Casie Kelly
Casie Kelly
Assistant Director of Licensing
University of California, Irvine
 
About Speaker:

Casie Kelly is the Assistant Director, Licensing at UCI Applied Innovation, Invention Transfer Group. Casie works closely with faculty, staff, and students at UCI to help identify aspects of their research with commercial potential. Her responsibilities include evaluating new inventions, managing all aspects of patent prosecution within her portfolio of inventions, and licensing the university’s patent rights to both established companies and startups. Casie also oversees ITG’s operations group which is responsible for patent prosecution, invention intake, invention analysis, and post agreement compliance. Prior to joining UCI in 2012, Casie worked for six years at UCLA’s technology transfer office, where she managed a large portfolio of life science inventions. Casie is a named inventor on 9 issued US patents and previously developed therapeutic monoclonal antibodies that are in clinical development. Casie earned her Ph.D. in Microbiology & Molecular Genetics from Harvard University and B.S. degrees in Chemistry and in Microbiology from UCLA. Casie is a registered patent agent at the USPTO.

Moderator:
Saikat Nandi
Saikat Nandi
Senior Research Associate
Cold Spring Harbor Laboratory
 
Saikat Nandi
Saikat Nandi
Senior Research Associate
Cold Spring Harbor Laboratory
 
About Speaker:

Dr. Saikat Nandi is a Senior Research Associate at the Cold Spring Harbor Laboratory (CSHL) and Business Development Consultant for the Long Island Bioscience Hub (LIBH), an NIH-designated and one of only three Research Evaluation and Commercialization Hub (REACH) facilities in the nation. Dr. Nandi also serves as an advisor to Salus Discovery, a start-up from the University of Wisconsin-Madison and Program Director for GTCbio Cancer Therapeutics and Partnering Summit. Dr. Nandi has over 10 years of experience in oncology and drug discovery and over 4 years of experience in technology commercialization and business development through his involvement in the organizations and financially successful start-up companies. Dr. Nandi received his D.Phil. (PhD) from Oxford University and has served as an Editor and Reviewer for over a dozen international scientific journals.

Array ( [5042] => Array ( [sheduleid] => 5042 [new_session] => 0 [single_conf] => 0 [cfid] => 342 [schedule_type] => speakerslot [prev] => 1506683100 [next] => 1506686100 )[5055] => Array ( [sheduleid] => 5055 [new_session] => 1 [single_conf] => 0 [cfid] => 343 [schedule_type] => speakerslot [prev] => 1506683100 [next] => 1506686100 )[5056] => Array ( [sheduleid] => 5056 [new_session] => 0 [single_conf] => 0 [cfid] => 343 [schedule_type] => speakerslot [prev] => 1506683100 [next] => 1506686100 )[5057] => Array ( [sheduleid] => 5057 [new_session] => 0 [single_conf] => 0 [cfid] => 343 [schedule_type] => speakerslot [prev] => 1506683100 [next] => 1506686100 )[5983] => Array ( [sheduleid] => 5983 [new_session] => 0 [single_conf] => 0 [cfid] => 343 [schedule_type] => speakerslot [prev] => 1506683100 [next] => 1506686100 )[6044] => Array ( [sheduleid] => 6044 [new_session] => 0 [single_conf] => 0 [cfid] => 343 [schedule_type] => speakerslot [prev] => 1506683100 [next] => 1506686100 ))
11:30
The Role of Innate Immunity in Regulating the Therapeutic Response to Anti-Angiogenic Agents
 
Napoleone  Ferrara
Napoleone Ferrara
Distinguished Professor of Pathology
University of California, San Diego Moores Cancer Center
About Speaker: Dr. Ferrara earned his M.D. degree in 1981 from the University of Catania Medical School in Italy.  After completing his postdoctoral research at the University of California, San Francisco, he joined Genentech Inc. in 1988.  It is there where he s... Read Full Bio 
 
 
Napoleone  Ferrara
Napoleone Ferrara
Distinguished Professor of Pathology
University of California, San Diego Moores Cancer Center
 
About Speaker:

Dr. Ferrara earned his M.D. degree in 1981 from the University of Catania Medical School in Italy.  After completing his postdoctoral research at the University of California, San Francisco, he joined Genentech Inc. in 1988.  It is there where he spent nearly 25 years working on the isolation, molecular cloning and biological characterization of  VEGF-A which resulted in the development of bevacizumab, the first anti-angiogenic agent to be approved by the FDA for cancer therapy.  His research also led to the development of ranibizumab, which has been FDA-approved for the treatment of multiple intraocular neovascular disorders.  In December 2012, Dr. Ferrara joined the University of California, San Diego as a Distinguished Professor of Pathology, Distinguished Adjunct Professor of Ophthalmology & Pharmacology, and Senior Deputy Director for Basic Science of the Moores Cancer Center.  He plans to continue his research focusing on the biology of angiogenesis and the identification of its regulators.  

Dr. Ferrara has authored over 300 scientific publications, which have been cited over 130,000 times according to Google Scholar.  He is also the recipient of numerous scientific awards, including the AACR Cain Memorial Award, the Lefoulon-Delalande-Institut de France Prize, the Passano Award, the General Motors Cancer Research Award, the ASCO Science of Oncology Award, the Pezcoller Foundation-AACR International Award, the Lasker-deBakey Clinical Medical Research Award, the Janssen Award for Biomedical Research, the Economist Innovation Award, the Breakthrough Prize in Life Sciences, the Antonio Champalimaud Vision Award and the Gairdner Foundation International Award.  Dr. Ferrara has been an elected member of the National Academy of Sciences, USA since 2006 and became an elected member of the National Academy of Medicine in 2015.

11:55
Immunotherapy-based Treatment Strategies for Gynecologic Malignancies
 
Yvonne Lin
Yvonne Lin
Medical Director, Product Development Oncology
Genentech-Roche
About Speaker: Yvonne Lin, MD, MS is a Medical Director in Product Development, Oncology at Genentech-Roche. Her current research focuses on cancer immunotherapy, particularly as it applies to gynecologic malignancies including ovarian and uterine cancers. Prior to... Read Full Bio 
 
 
Yvonne Lin
Yvonne Lin
Medical Director, Product Development Oncology
Genentech-Roche
 
About Speaker:

Yvonne Lin, MD, MS is a Medical Director in Product Development, Oncology at Genentech-Roche. Her current research focuses on cancer immunotherapy, particularly as it applies to gynecologic malignancies including ovarian and uterine cancers. Prior to joining Genentech, Yvonne was a physician-scientist and assistant professor of gynecologic oncology and obstetrics and gynecology at the University of Southern California. As an NCI K08-funded investigator, she studied the effects of endoplasmic reticular stress on endometrial cancer development and potential opportunities for prevention. She was also the GOG/NRG Study Chair of the NCI-CTEP sponsored GOG9929, a phase 1 study of sequential ipilimumab after definitive chemoradiation for patients with newly diagnosed high-risk locally advanced cervical cancer. She received her SB from MIT, her MS in epidemiology from Harvard School of Public Health, and her MD from UC Irvine. She completed Ob-Gyn residency at the Beth Israel Deaconess Medical Center in Boston, then gynecologic oncology fellowship at the M.D. Anderson Cancer Center. Yvonne is a long-time supporter of the Pasadena Humane Society since adopting Sally, her Belgium Malinois from there in 2011. In her spare time, Yvonne enjoys snowboarding, spinning, and yoga.

 
Abstract: Contemporary immunotherapies have led...Read More 

Contemporary immunotherapies have led to great successes for some cancer patients. However, room for improvement exists for many patients, including women with gynecologic malignancies. Recent molecular details about ovarian-, endometrial-, and cervical cancer highlight opportunities to harness the immune response in therapeutic strategies. This talk will discuss the interplay of the immune response with gynecologic malignancies and present opportunities to enhance clinical efficacy of contemporary immunotherapies using combinatorial approaches.

 Read Less
ssclaas=mixsessionprlval=1Array ( [342] => 1 )
12:20
Lunch Provided by GTCbio
ssclaas=mixsessionprlval=1Array ( [342] => 1 )
ssclaas=parallelprlval=0Array ( [342] => 3 )
Array ( [5858] => Array ( [sheduleid] => 5858 [new_session] => 1 [single_conf] => 0 [cfid] => 342 [schedule_type] => speakerslot [prev] => 1506692100 [next] => 1506697200 )[5859] => Array ( [sheduleid] => 5859 [new_session] => 0 [single_conf] => 0 [cfid] => 342 [schedule_type] => speakerslot [prev] => 1506692100 [next] => 1506697200 )[5860] => Array ( [sheduleid] => 5860 [new_session] => 0 [single_conf] => 0 [cfid] => 342 [schedule_type] => speakerslot [prev] => 1506692100 [next] => 1506697200 ))
ssclaas=mixsessionprlval=1Array ( [342] => 1 )
3:00
Summit Concludes